|Home | About | Journals | Submit | Contact Us | Français|
A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.
The literature has clearly established that antipsychotics can cause catatonia [1, 2]. Catatonia cases secondary to the intake of both first-generation [1–3] and second-generation antipsychotics [2, 4] have been described. There may be a spectrum between antipsychotic-induced catatonia and neuroleptic malignant syndrome (NMS) [5–7]. The incidence of NMS has been reduced after the introduction of second-generation antipsychotics . A differential characteristic from clozapine is that it has been associated with NMS only on rare occasions. In a review of 68 published NMS cases associated with second-generation antipsychotics, there were 21 clozapine cases . Most of the NMS cases associated with clozapine demonstrated atypical presentations [8, 9]. In spite of these cases, clozapine may be the best antipsychotic for rechallenging patients who developed NMS with other antipsychotics . Manu et al.  reviewed the cases of five clozapine-induced NMS patients who were rechallenged with clozapine using slow titrations and creatinine kinase (CK) monitoring; all five rechallenges were successful and did not result in NMS.
Another characteristic which makes clozapine appear different from the majority of antipsychotics is that abrupt clozapine discontinuation is frequently associated with withdrawal symptoms . Clozapine is characterized by blocking multiple receptors including the dopamine, muscarinic, serotonergic, histaminic, and α1 adrenergic receptors. In a review on clozapine withdrawal, Verghese et al.  proposed that time course and clinical features of clozapine withdrawal may be explained by cholinergic overdrive and gamma-aminobutyric acid (GABA) supersensitivity. After clozapine withdrawal, some individuals have symptoms suggestive of a cholinergic rebound including nausea, vomiting, diarrhea, headache, agitation, confusion, and diaphoresis. These symptoms are probably explained by the antimuscarinic properties of clozapine and appear to respond to anticholinergic treatment . Other individuals appear to have worsening psychosis and/or abnormal movements . More importantly, in very rare instances, clozapine withdrawal has been associated with catatonic symptoms [15–24]. Table 1 describes the 9 cases that we identified in a PubMed search (Footnote 1). Catatonia episodes were rediagnosed using the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction Causality Assessment Tool (LADRCAT) is used to assess adverse drug reaction (ADR) causality . We modified it to retrospectively assess ADRs secondary to drug withdrawal. Then, we used the Modified LADRCAT (MLADRCAT) (Figure 1) to establish the likelihood that clozapine withdrawal caused the catatonia episodes in prior published cases (last column in Table 1) and in our patient who developed three catatonic episodes after three instances of sudden clozapine withdrawal.
The DSM-5 Criterion A requires having ≥3 of the 12 listed catatonic symptoms needed to make the diagnosis. After reviewing all available information, the first and last authors discussed and agreed on the presence of DSM-5 Criterion A in our patient and in 7 of 9 of the previously published cases.
The LADRCAT  allows the diagnosis of an adverse drug reaction (ADR) while a drug is used for treatment, but it provides no system for diagnosing an ADR after drug withdrawal. To retrospectively assess the likelihood that clozapine withdrawal caused the catatonia episode, we modified the scale (MLADRCAT). This modified scale established the probability that clozapine withdrawal explained the three catatonic episodes of our patient (FiguresS10–S12 in Supplementary Material available online at https://doi.org/10.1155/2017/2402731) and the catatonic episodes of previously published cases (FiguresS1–S9).
The commercial laboratory tests routinely used by the psychiatric state hospital were employed to measure trough steady-state serum clozapine and norclozapine concentrations in ng/mL. The mean ± standard deviation (SD) for serum concentrations is described for clozapine, norclozapine, and the total (adding both). The recommended therapeutic range for trough serum clozapine concentration is 350–600ng/mL . Serum CK levels (normal laboratory range: 21–232IU/L) were used as an objective measure of catatonia severity .
The patient was a single, unemployed, African American male with a psychiatric history of longstanding DSM-5 schizophrenia. He was treated with haloperidol decanoate and had a history of mixed substance abuse (including alcohol, cocaine, and Cannabis) but did not smoke tobacco. The patient had a family history positive for schizophrenia in a brother and paternal uncle. He graduated from high school. His history included multiple arrests and revolving door admissions (Figure 2).
His psychiatric treatment first started as an outpatient with haloperidol decanoate at 18 years of age. His first psychiatric admission to the first state psychiatric hospital was at the age of 27 and lasted almost 1 month. His second admission was at the age of 30 and lasted 6 days. He had no catatonic symptoms during these first two admissions.
The third hospitalization at the age of 30 was a result of medication noncompliance in the community. On day 1 of the third admission (used as day 1 of the long follow-up of this patient), his presenting symptoms included markedly disorganized thinking, bizarre behavior, poor self-care, social withdrawal, aggressiveness towards his brother, suspicion, and hallucinations leading to an involuntary admission per court order. During this admission, he was also diagnosed with obesity, hypertension, and dyslipidemia. The medical treatment included hydrochlorothiazide 25mg/day on day 281. On day 438, two medications were added: simvastatin 20mg/day and metoprolol 12.5mg/day (increased to 100mg/day on day 460).
During this third hospital admission, the patient's symptoms remained refractory to high doses of oral and decanoate haloperidol, olanzapine, and high doses of risperidone. Clozapine was started on day 190 at 25mg/day and a stable dose of 400mg/day was reached on day 228. Clozapine provided some improvement for the patient's symptoms. On day 392, a Mini-Mental Status Examination (MMSE) was administered to the patient with scores of 29/30 with WORLD backwards and 27/30 with serial 7s on the MMSE. This score is normal for his age and education . On the MMSE, the abnormal results were serial 7s (3/5) and copying the two intersecting pentagons incorrectly. Brief Psychiatric Rating Scale-Anchored (BPRS-A)  provided a score of 37; abnormal items were severe suspiciousness, severe unusual thought content, moderately severe bizarre behavior, mild self-neglect, moderately severe disorientation, mild conceptual disorganization, moderately severe blunted affect, and moderate mannerisms and posturing. An Abnormal Involuntary Movement Scale (AIMS) exam  demonstrated some minimal movements in the tongue and lower 2 extremities and mild movements in the upper extremities.
He received an aripiprazole augmentation trial of clozapine from day 442 to day 532 up to 30mg/day and of quetiapine up to 600mg/day from day 532 to day 631. Then, the process of switching augmentation from quetiapine to ziprasidone was started on day 631.
On day 659 when he was taking clozapine 400mg/day (plus 200mg/day of quetiapine and ziprasidone 120mg/day), he ran away and had no access to any psychiatric (or medical) medication in the community.
During the prior 14 months when he was taking 400mg/day of clozapine, his serum clozapine concentration was 511 ± 79 (range: 372–675), norclozapine concentration was 383 ± 80 (range: 194–507), and total clozapine concentration was 894 ± 129 (range: 566–1061).
On day 672, 14 days after running away from the psychiatric hospital and not receiving any other clozapine dose, he was arrested by the police and incarcerated; then, he was taken to the university hospital. He was diagnosed with dehydration, hypernatremia, hypochloremia, rhabdomyolysis, catatonic schizophrenia, hypertension, and hyperlipidemia. He had a normal head computerized tomography (CT) scan. The urine drug screen was positive only for clozapine; sodium was 150mEq/L; chloride was 113mEq/L; and he had an elevated CK of 1838IU/L which decreased to 823IU/L during admission. He was treated supportively with fluids. On day 673, he was discharged back to jail. Within 24 hours, he was found unresponsive and with urinary incontinence and was sent back to the university hospital on day 674. There, he was treated intermittently with doses of intravenous (IV) lorazepam 1mg (we are unsure of the total dose) and quetiapine 25mg/day. The patient refused food and drink during the entirety of the admission at the university hospital. On day 678, he was transferred back to the psychiatric state hospital where he presented limited interaction with his environment, poor eye contact, posturing of the left arm, stereotypic movement in the fingers, negativistic behavior, and bursts of dyskinetic movements. He was oppositional to any movements in all directions.
On day 678, he arrived at the psychiatric hospital. He received 4mg lorazepam intramuscularly (IM) and within two hours he began drinking and he was able to take some steps and sit in a chair. He was psychotic and disoriented to location. Three hours later, he received 4mg lorazepam (a total of 8mg for day 678).
The next day (day 679), he received a total of 14mg of lorazepam with minimal results. He was able to eat; however, he had urinary incontinence and a paucity of speech. On day 680, the patient appeared worse and was started on lorazepam 16mg/day. There was mild improvement in catatonic symptoms; he was able to say two sentences every 5 minutes and was able to stand up and walk with help. He was also able to eat unassisted. After day 681, lorazepam 16mg/day was scheduled until day 698. He was slowly improving and at times became hostile and possibly psychotic. On day 683, ziprasidone 80mg/day was started for these symptoms; however, it was discontinued the next day. Over the next week, the patient's catatonic symptoms improved but he only mumbled “OK” when spoken to.
Lorazepam was reduced to 8mg/day within 1 month of his catatonic presentation (on day 700). The patient was tapered to 2mg/day over the next few weeks; however, his symptoms exacerbated and he was kept on 4mg/day for the next few months. Lorazepam was eventually switched to clonazepam, which was finally discontinued on day 1332.
The patient remained catatonia-free during the next 2 years of his admission before he was discharged on day 1517. He was discharged on 400mg/day of clozapine.
His fourth admission to the psychiatric hospital, 3 months after discharge, lasted 3 months. His discharge psychiatric medications included clozapine 600mg/day, oral haloperidol 15mg/day, 100mg of haloperidol decanoate every 3 weeks, and benztropine 2mg/day at night. His fifth admission to the psychiatric hospital was seven months later and lasted 2 months. His discharge medications did not include clozapine. His sixth admission to the psychiatric hospital was 7 months later and lasted 10 months. His discharge medications from the sixth admission included clozapine 600mg/day and diphenhydramine 50mg at night. In summary, during these 3 admissions, he did not have catatonic symptoms.
The patient was readmitted to the psychiatric hospital 18 days after the last discharge (6th admission) when the police brought him in after he was discovered sitting on the street for 8-9 hours that day.
On arrival at the psychiatric hospital on day 2509, the patient did not speak or move, he appeared to be responding to internal stimuli, he maintained poor eye contact, and he was malodorous and dirty. The patient had an elevated temperature (38.9°C), lower extremity edema, elevated heart rate and blood pressure, and a CK of 1943IU/L.
He was sent to the emergency room at the university hospital the next day and was transferred to the intensive care unit where he was treated with IV fluids and IV antibiotics for a urinary tract infection. He was given 1mg of lorazepam IV and then doses of 1 or 2mg IV every 2 hours reaching up to 24mg/day. He was also treated with a clonidine patch 0.1mg/day and subcutaneous heparin 1500 units/day for preventing deep vein thrombosis. Head CT scan and echocardiogram were normal. After 5 days, he was returned to the psychiatric hospital after the CK was normalized.
On day 2514 when he came back to the psychiatric hospital, he was prescribed 22mg/day IM lorazepam. The lorazepam taper took more than 3 months because there were 4 episodes suggestive of catatonic decompensation which required increasing the lorazepam dose again. Finally, on day 2649, lorazepam was completely and definitively stopped.
On day 2649, the same day lorazepam was discontinued, clozapine 50mg/day was started. It was increased up to 400mg/day on day 2720.
On day 2903, his discharge medications from the seventh admission included clozapine 400mg/day.
In the last 4 months, the five measured concentrations were 624 ± 69 (range: 504–684) for clozapine, 396 ± 97 (range: 253–520) for norclozapine, and 1020 ± 158 (range: 757–1167) for the total.
Six days after discharge, the patient was arrested and at that time he had the complete clozapine supply that he was given on discharge, indicating that he had not taken any clozapine tablets after leaving the hospital. He spent another 4 days in jail; then, after a total of ten days without clozapine, he was readmitted during his third catatonic episode for his 8th psychiatric admission. While in jail, the patient was described by law enforcement as not following directions or answering questions. He was brought to the psychiatric inpatient state hospital on the evening of day 2913 where his initial assessment described him as mute, not cooperative, displaying poor eye contact, and paying little attention to the interviewer. He had reduced psychomotor activity; he would sit very still; however, he would then abruptly start pacing around the room, and at one point he was pacing and then stopped and urinated. He also had some choreoathetoid movements in his fingers. This catatonic presentation was similar to the other 2 prior episodes.
The charted information on the response to treatment and the justification for the treatment decisions during this third catatonic episode were much more limited than in prior episodes. During the third catatonic episode, there was a psychiatrist at the psychiatric hospital who started high doses of IM lorazepam but this treatment was tapered at the university hospital when the patient was admitted for serious dehydration.
In the first two days after coming from jail to the psychiatric hospital on day 2913, the patient refused to take oral medications and received IM cocktails with lorazepam 2mg, diphenhydramine 50mg, and haloperidol 5mg. On day 2916, the patient was not eating or drinking, was mute, refused medications, and had periods of prolonged standing and staring, along with negativism. He received lorazepam 4mg IM on that day. On the fourth day (day 2917), he received 12mg of lorazepam IM and on the fifth day (day 2918) he received 16mg of lorazepam IM. He showed clear signs of dehydration with blood urea nitrogen (BUN) of 32 mMol/L (range: 7–18), a sodium level of 157mEq/L (range: 136–145), and CK elevation to 2307U/L. Due to these lab abnormalities, on the sixth day (day 2919), the patient was sent back to the university hospital. His head CT scan was normal. He was diagnosed with catatonia and given IV fluids, and within 2 days his CK levels returned back to normal. The medical hospital discontinued all of his medications except oral lorazepam which was decreased to 3mg/day.
He was transferred back a second time to the psychiatric hospital on day 2921. On that day, the patient continued to portray catatonic symptoms; he would sit still with his lunch on his lap and not eat even when encouraged by staff. Staff stated that he did not react to his external environment. He was prescribed no medication for 4 days. Six days later, he was prescribed 8mg/day of lorazepam and 400mg/day of clozapine. He had a third short admission to the university hospital for less than 2 days.
The patient appeared to improve from the catatonic symptoms due to the use of lorazepam, but it was used intermittently. Clozapine treatment was started first by adding it to lorazepam on day 2926. The patient took up to 400mg/day intermittently until day 2941. During that time, he required frequent haloperidol and diphenhydramine injections, until a forced medication order was approved by the court. After that, a second trial of clozapine was started on day 2976 with 25mg/day and slowly titrated up. His clozapine dose was slowly increased to 400mg/day (on day 3079) and then to 600mg/day (day 3140). This second clozapine trial led to a complete and definitive recovery from the catatonic episode.
Shortly after that, the patient first collaborated with weight measurements, which indicated that he had lost 25Kg during the catatonic episode. Before completing the third year of this 8th admission, on day 3603, at 41 years of age, the patient was transferred to a state nursing home for psychiatric patients. His discharge medications were clozapine 700mg/day, metoprolol extended release 50mg/day, simvastatin 20mg/day, memantine 10mg/day, and aspirin 81mg/day. He stayed on clozapine until day 4084. On day 4129, he was transferred to another state psychiatric hospital located near the state nursing home. Since then, he has had another 4 admissions to this second state psychiatric hospital. The fifth admission started on day 4974 and has lasted more than 1 year. His current age is 44 years. Clozapine has never been prescribed during any of the 5 admissions to this second state psychiatric hospital.
Each one of the three catatonic episodes was diagnosed at the time of presentation and retroactively by us through chart data using DSM-5 criteria (including negativism, mutism, and stupor). In all three episodes, CK levels were elevated and medical hospitalization and intravenous fluids were needed.
All the authors agreed that the modified LADRCAT was definite in all three episodes indicating that the catatonic episodes were secondary to clozapine withdrawal. No other catatonic episodes were described from ages 17 to 42 years, indicating that the patient did not have any other cause of catatonia.
The first and third catatonic episodes occurred after sudden withdrawal from 400mg/day while the second was after withdrawal from 600mg/day. In the first and second episodes, we have some idea of the patient's serum clozapine concentrations before the sudden withdrawal. As far as we can tell, the patient stopped clozapine suddenly after leaving the hospital (running away in the first episode or after prior discharge instances in the second and third episodes). An exact onset of the catatonic symptoms can only be approximated since the first and third catatonic episodes started in jail and in the second episode the patient was brought by the police after sitting for 8-9 hours on the street. At the hospital, the catatonic symptoms in the three episodes were definitely described between 10 and 18 days after sudden withdrawal of clozapine. After 1 week of sudden discontinuation of therapeutic serum clozapine concentrations, clozapine may disappear completely from the body .
During the first 2 episodes, the patient was treated for extended periods of time with high doses of lorazepam. In the first episode, he received 16mg/day lorazepam for three weeks before significant improvements in his symptoms were documented and the dosage started to be tapered. During the second catatonic episode, he received up to 24mg/day and slowly improved over a period of months due to multiple premature tapering attempts of lorazepam. In the third episode, the patient received 16mg/day for only one day before being tapered to 8mg/day. Clozapine up to 400mg/day was prescribed but the patient was noncompliant with it. After a second and definitive clozapine trial during this third catatonic episode, the patient recovered completely from the catatonic symptoms. Due to medication noncompliance and lack of consistent treatment with lorazepam and/or clozapine, it took almost 3 months before the catatonic symptoms were resolved, after adding clozapine a second time.
Unlike other similar cases in the literature which required much lower lorazepam doses for resolution of symptoms, this patient required very high doses. The authors theorize that this patient may have required such high doses due to adaptation and desensitization of the benzodiazepine receptors due to the low dose exposure of lorazepam. In the first episode, the patient received 1mg of lorazepam IV as needed at the university hospital for 4 days; the total dosage amount is uncertain. In the second episode, the patient responded to a high dose of 24mg/day, prescribed after the last author's recommendation.
A literature review identified 9 other cases of clozapine-withdrawal catatonia (Tables (Tables11 and and2).2). In 2 of the 9 cases, we were unable to make the catatonia diagnosis for the reduced number of symptoms described in the published articles [22, 23]. In the remaining 7 cases [15–21], the authors described ≥3 DSM-5 catatonia symptoms (Table 2).
The MLADRCAT was applied to the 7 previously published cases of DSM-5-diagnosed catatonia. Three of the 7 cases were classified as “definite” catatonia after clozapine withdrawal and four as “probable” (Table 1). One of the 7 cases was reported to have included catatonia episodes independent of clozapine withdrawal. In the 7 previously published cases, the onset of catatonic symptoms after clozapine withdrawal ranged from 1.5 to 7 days versus 10–18 days in our patient (Table 1).
In the 7 previously published cases, treatment varied including oral/IM lorazepam, clozapine, and ECT (Table 2). Resolution of symptoms in the literature ranged from 4 days to 3 weeks (Table 2). Our patient received high doses of lorazepam as a treatment for all 3 of his catatonic episodes; however, during his third episode, he only received a high lorazepam dose (16mg) for 1 day before becoming dehydrated and requiring hospitalization. He was restarted on a lower dose of only 8mg/day lorazepam with adjunct clozapine 400mg/day taken intermittently due to noncompliance. He finally recovered from the third catatonic episode during a second and definitive clozapine trial.
The psychiatric diagnosis in the 7 previously published cases included 5 with schizophrenia and 2 with schizoaffective disorder. Our patient was diagnosed with schizophrenia.
A pharmacological model of catatonia secondary to clozapine withdrawal is hypothesized after reviewing three pieces of literature data suggesting that clozapine may have agonist properties at the GABA receptors: (1) clozapine studies on GABA neurotransmission; (2) the existence of cases of a rare pharmacodynamic drug-drug interaction (DDI) when starting clozapine in patients taking benzodiazepines; and (3) two cases of clozapine intoxication who responded to flumazenil, a benzodiazepine antagonist at the GABA receptor.
In a transcranial magnetic stimulation study, Kaster et al.  concluded that clozapine treatment is associated with an increase in GABAB mediated inhibitory transmission. An in vitro study described clozapine as inhibiting GABA-evoked chloride currents at recombinant GABAA receptors . In a rat study, Bragina et al.  suggested that clozapine increases GABA activity by upregulating vesicular GABA transporters (VGAT) in the frontal cortex. In an animal study, Marx et al.  proposed a different mechanism that suggests that clozapine may indirectly increase GABA activity by releasing the neurosteroid, allopregnanolone. Finally, not all studies agree that clozapine has GABA agonist properties; in a 2000 in vitro study using a culture of ventral tegmental neurons, Michel and Trudeau proposed that in that model clozapine may have an inhibitory effect on GABAA receptors .
A poorly understood pharmacodynamic DDI between clozapine and benzodiazepines has been described in a few individuals, usually leading to severe ADRs within 48 hours after the first clozapine dose in patients taking benzodiazepines. The ADRs secondary to this DDI may include lethargy, ataxia, loss of consciousness, and, rarely, respiratory arrest. Sassim and Grohmann  first reported two cases; then, they reviewed 959 patients taking clozapine and found 4 cases of severe cardiovascular and respiratory dysregulation during the combination of clozapine-benzodiazepines at the beginning of the clozapine titration . Finkel and Schwimmer  reported 7 cases of respiratory arrest after treating 12,000 individuals, but only in 2 of these cases did the documentation associate them with the combination of benzodiazepines and the first clozapine doses. Klimke and Klieser  reported that, of 162 individuals treated with the combination of clozapine and benzodiazepines in a German hospital, 1 death by respiratory arrest occurred in an individual suffering from liver impairment. Faisal et al.  reviewed company data and found (1) 6 US cases of respiratory depression/arrest in combination clozapine-benzodiazepine treatment in 15,311 clozapine patients and (2) 10 European cases of cardiorespiratory arrest within the first 3 days (some taking benzodiazepines) in 63,000 patients. Bitter et al.  proposed that this DDI is rare. In conclusion, the occurrence of respiratory arrest during the coadministration of benzodiazepines and clozapine appears to be a very rare idiosyncratic reaction in the first days of clozapine treatment. The most reasonable explanation of this DDI is that clozapine and benzodiazepines may have additive properties at the GABA receptors which manifest in this way in rare individuals.
Peetoom and Schulte  published 2 cases in which flumazenil reversed comas secondary to adding clozapine to low doses of benzodiazepines. A 77-year-old female was taking other medications and 20mg/day of oxazepam, but she went into a coma after erroneously taking 100mg clozapine, 10mg oxazepam, and 400mg norfloxazine. She quickly recovered from the coma with 0.5mg of flumazenil. A 44-year-old female with Huntington's disease was taking 6mg/day of diazepam and 75mg/day of oxazepam and other medications. She was titrated to 175mg/day of clozapine within 14 days and went into a coma 2 hours after administration of her benzodiazepine medications. The patient awoke from the coma after the administration of 0.5mg flumazenil . That a coma induced by the combination of clozapine and benzodiazepines responded to flumazenil suggests that the coma may be explained by the additive effects of these drugs at the GABA receptors.
According to the literature, dysregulation of the GABA receptors may contribute to catatonia. Hauser et al.  and Rosebush and Mazurek  described catatonic episodes during sudden benzodiazepine withdrawal. Carroll  described a patient with no previous history of catatonia who developed catatonia after abrupt withdrawals of benzodiazepines (GABAA allosteric agonists) and baclofen (GABAB agonist) . In a review of catatonia after sedative withdrawal, Oldham and Desan  reviewed prior published cases and added new ones including 16 cases of benzodiazepines, 4 cases of benzodiazepines mixed with other sedative drugs, and 6 cases of alcohol withdrawal. Similar to the benzodiazepines, ethanol had also been described as an allosteric GABAA agonist  and chronic alcoholism had been associated with GABAA downregulation . Oldham and Desan proposed that catatonia and delirium may be a spectrum of disorders associated with GABA receptor dysregulation .
In summary, if clozapine has GABA agonist properties, sudden clozapine withdrawal may explain GABA dysregulation with sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. In that sense, based on prior cases and on our case, the treatment for catatonia secondary to clozapine can be benzodiazepines and/or restarting clozapine. In the USA, there is no parenteral clozapine; therefore, parenteral benzodiazepines may be required if the patient cannot take oral clozapine.
The most important limitation of this case description is that the chart data is not detailed enough to know how catatonic symptoms responded to treatment in all 3 catatonic episodes. Ideally, one would have liked to have catatonia scales, standardized treatments not by multiple physicians, and exact descriptions of symptom onset before coming to medical attention. Even with its limitations, this is the first article with a careful description of 3 repeated episodes of catatonia secondary to sudden clozapine withdrawal and it includes a careful follow-up for decades (Figure 2), which is very rare in published case reports in psychiatry.
The LADRCAT was modified to assess ADRs secondary to drug withdrawal. This modified scale was used to assess 7 previously published cases of catatonia secondary to clozapine withdrawal and established that 3 were definitive and 4 probable. Another definitive case was described with three catatonic episodes which (1) occur after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum CK elevation, and (3) required medical hospitalization and IV fluids. Clozapine may be a GABA agonist and sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on prior cases and on our case, the treatment for catatonia secondary to sudden clozapine withdrawal can be benzodiazepines and/or restarting clozapine.
Twelve MLADRCAT figures: nine from previously published patients (Figures S1–S9) and three catatonic episodes of our patient (Figures S10–S12).
Lorraine Maw, M. A., at the UK Mental Health Research Center helped with editing.
No commercial organizations had any role in the completion or publication of this article.
The authors declare no conflicts of interest during the last 36 months.